Animal Biosciences Announces New Canine Clinical Research Evaluating Reversal of Age-Related Signs in Dogs
Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.
- Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.
- After five years of development and testing in dogs, leveraging discoveries made at Harvard Medical School, the study shows the first clinical evidence that it is possible to reverse age-related decline in dogs.
- "The outcomes of the clinical trial, especially the enhancements in cognition, are encouraging and represent a unique achievement,” Dr. Olby noted.
- In senior dogs, as in humans, this age-related decline can manifest as cognitive decline, increased frailty and lower engagement.